Addressing obesity and fibromyalgia are essential components to managing the most complex patients with psoriatic arthritis, ...
Skye Bioscience's nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when ...
Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes. Read why I rate BMEA stock a ...
GlobalData on MSN
Skye’s shares crash down to earth on Phase II obesity loss
Though nimacimab failed to trigger weight loss as a monotherapy, analysts are intrigued by the drug’s activity alongside ...
Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.
MedPage Today on MSN
HRT May Get Revised Label; Costco to Sell No-Insurance Ozempic; CGM Without Diabetes
Among men with diabetes and hypogonadism, use of testosterone therapy was associated with reductions in acute kidney injury, kidney failure requiring replacement therapy, major cardiovascular events, ...
Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.
Sagimet Biosciences (SGMT) is well-positioned financially, with $135 million in cash and minimal debt, supporting operations ...
Zacks Investment Research on MSN
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Shares of Skye Bioscience SKYE crashed 60% on Monday after the company failed to meet the key goal in a mid-stage proof-of-concept study of its only pipeline candidate, nimacimab, for obesity. The ...
A pharmacist with 30 years of experience has issued a warning about the use of weight loss injections, citing “alarming” side ...
Experts warn the strange side effect could lead to delayed diagnoses and treatments, as well as unnecessary medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback